CoChat

Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

The advent of effective targeted therapeutics has led to increasing emphasis on precise biomarkers for accurate patient stratification. Here, we describe the role of ACK1, a non-receptor tyrosine kinase in abrogating migration and invasion in KRAS mutant lung adenocarcinoma. Bosutinib, which inhibits ACK1 at 2.7 nM IC50, was found to inhibit cell migration and invasion but not viability in a panel of non-small cell lung cancer (NSCLC) cell lines. Knockdown of ACK1 abrogated bosutinib-induced inhibition of cell migration and invasion specifically in KRAS mutant cells. This finding was further confirmed in an in vivo zebrafish metastatic model. Tissue microarray data on 210 Singaporean lung adenocarcinomas indicate that cytoplasmic ACK1 was significantly over-expressed relative to paired adjacent non-tumor tissue. Interestingly, ACK1 expression in "normal" tissue adjacent to tumour, but not tumour, was independently associated with poor overall and relapse-free survival. In conclusion, inhibition of ACK1 with bosutinib attenuates migration and invasion in the context of KRAS mutant NSCLC and may fulfil a therapeutic niche through combinatorial treatment approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-13-13

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Bosutinib inhibit KRAS mutant cell migration and invasion but not KRAS wildtype cells. The serum-starved KRAS (A & C) mutant and (B & D) wildtype cells were trypsinized and seeded in the upper chamber of the Transwell (8 mm pore, A &B) or Matrigel™ (C & D), in the presence of DMSO or bosutinib at various concentrations (0.1, 0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.1, 0.5 and 1 μM) was used as chemoattractant in the lower chamber. The migrated or invaded cells were fixed and stained with 0.5% crystal violet blue after 6 h and 24 h respectively. Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five random fields counted. The percentage of migrated or invaded cells was expressed with respect to the DMSO treated cells.
Figure 1 Bosutinib inhibit KRAS mutant cell migration and invasion but not KRAS wildtype cells. The serum-starved KRAS (A & C) mutant and (B & D) wildtype cells were trypsinized and seeded in the upper chamber of the Transwell (8 mm pore, A &B) or Matrigel™ (C & D), in the presence of DMSO or bosutinib at various concentrations (0.1, 0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.1, 0.5 and 1 μM) was used as chemoattractant in the lower chamber. The migrated or invaded cells were fixed and stained with 0.5% crystal violet blue after 6 h and 24 h respectively. Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five random fields counted. The percentage of migrated or invaded cells was expressed with respect to the DMSO treated cells.CC BY · PubMed Central
Figure 2 Effect of bosutinib on viability of NSCLC cell lines is independent of KRAS status. The KRAS mutant (A) and wildtype (B) NSCLC or Normal Human Bronchial Epithelial (NHBE) cells were seeded onto 96-well plates for 24 h. The cells were treated with various concentrations (0–10 μM) of bosutinib for 72 h followed by cell viability assay measured by CellTitre Glo. The cell viability results were normalized to DMSO-treated controls and expressed in percentage. (C) Four NSCLC cells were treated with bosutinib for 72 h at different concentrations. Caspase3/7 activities were measured using Caspase-Glo 3/7 luminescent assay kit. The enzymatic activity is expressed as the value with respect to untreated cells.
Figure 2 Effect of bosutinib on viability of NSCLC cell lines is independent of KRAS status. The KRAS mutant (A) and wildtype (B) NSCLC or Normal Human Bronchial Epithelial (NHBE) cells were seeded onto 96-well plates for 24 h. The cells were treated with various concentrations (0–10 μM) of bosutinib for 72 h followed by cell viability assay measured by CellTitre Glo. The cell viability results were normalized to DMSO-treated controls and expressed in percentage. (C) Four NSCLC cells were treated with bosutinib for 72 h at different concentrations. Caspase3/7 activities were measured using Caspase-Glo 3/7 luminescent assay kit. The enzymatic activity is expressed as the value with respect to untreated cells.CC BY · PubMed Central
Figure 3 Bosutinib inhibit cell migration and invasion is ACK1 dependent and SRC- independent. NCI-H1792 were transfected with siRNA (control, ACK1 or SRC) using Oligofectamine for 72 h. The cells were harvested at 72 h. (A) Quantitative real-time PCR analysis was performed using 20 ng of cDNA and respective primers set for ack1 and src and normalized to gapdh. The serum-starved cells were trypsinized and seeded in upper chamber of the Transwell (8 mm pore, B) or Matrigel™ (C), in the presence of DMSO or bosutinib at various concentrations (0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.5 and 1 μM) was used as chemoattractant in the lower chamber. The cells were fixed and stained with 0.5% crystal violet blue after 6 h (migration, B) and 24 h (invasion, C). Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five random fields counted.
Figure 3 Bosutinib inhibit cell migration and invasion is ACK1 dependent and SRC- independent. NCI-H1792 were transfected with siRNA (control, ACK1 or SRC) using Oligofectamine for 72 h. The cells were harvested at 72 h. (A) Quantitative real-time PCR analysis was performed using 20 ng of cDNA and respective primers set for ack1 and src and normalized to gapdh. The serum-starved cells were trypsinized and seeded in upper chamber of the Transwell (8 mm pore, B) or Matrigel™ (C), in the presence of DMSO or bosutinib at various concentrations (0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.5 and 1 μM) was used as chemoattractant in the lower chamber. The cells were fixed and stained with 0.5% crystal violet blue after 6 h (migration, B) and 24 h (invasion, C). Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five random fields counted.CC BY · PubMed Central
Figure 4 Reduction of lung cancer cell metastasis in zebrafish embryos by bosutinib is ACK1 dependent. Embryo injected with Vibrant DiD labeled NCI-H2009 cells showing tumor foci burden determined by segmented red channel (upper) and scatter plot representation of cell dissemination (bottom). Each data series represents one fish and number of injected embryos from 3 biological replicates is indicated (n). Comparative inhibition of cell migration, as measured by Migration Index, between untreated and drug pretreated cells is represented as bar graph (right), Mean ± SD. (A) Embryos injected with NCI-H2009 transfected with control siRNA. (B) Embryos injected with NCI-H2009 transfected with SRC siRNA. (C) Embryos injected with NCI-H2009 transfected with ACK1 siRNA.
Figure 4 Reduction of lung cancer cell metastasis in zebrafish embryos by bosutinib is ACK1 dependent. Embryo injected with Vibrant DiD labeled NCI-H2009 cells showing tumor foci burden determined by segmented red channel (upper) and scatter plot representation of cell dissemination (bottom). Each data series represents one fish and number of injected embryos from 3 biological replicates is indicated (n). Comparative inhibition of cell migration, as measured by Migration Index, between untreated and drug pretreated cells is represented as bar graph (right), Mean ± SD. (A) Embryos injected with NCI-H2009 transfected with control siRNA. (B) Embryos injected with NCI-H2009 transfected with SRC siRNA. (C) Embryos injected with NCI-H2009 transfected with ACK1 siRNA.CC BY · PubMed Central
Figure 5 ACK1 is highly expressed in lung adenocarcinoma. Immunohistochemistry staining was performed on 210 NSCLC tumor and paired non-tumor sections on an in-house TMA using anti-ACK1 (C20, see material and method). (A) ACK1 immuno-positivity was defined as presence of brown cytoplasmic staining. Staining intensity was scored as 0, 1+, 2+ and 3+ (no, weak, moderate and strong staining, respectively). (B) Percentage of positively stained tumor cells was assessed as proportion of total number of tumor cells present in the section. Intensity percentage score, IP, was defined as product of the maximum immunostaining intensity and percentage of tumor cells stained.
Figure 5 ACK1 is highly expressed in lung adenocarcinoma. Immunohistochemistry staining was performed on 210 NSCLC tumor and paired non-tumor sections on an in-house TMA using anti-ACK1 (C20, see material and method). (A) ACK1 immuno-positivity was defined as presence of brown cytoplasmic staining. Staining intensity was scored as 0, 1+, 2+ and 3+ (no, weak, moderate and strong staining, respectively). (B) Percentage of positively stained tumor cells was assessed as proportion of total number of tumor cells present in the section. Intensity percentage score, IP, was defined as product of the maximum immunostaining intensity and percentage of tumor cells stained.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 66

Metadata

Authors
Tan, D. S., Haaland, B., Gan, J. M., Tham, S. C., Sinha, I., Tan, E. H., Lim, K. H., Takano, A., Krisna, S. S., Thu, M. M. M., Liew, H. P., Ullrich, A., Lim, W.-T., & Chua, B. T.
Affiliations
  • National Cancer Centre Singapore (SG)
  • National University of Singapore (SG)
  • Agency for Science, Technology and Research (SG)
  • Singapore General Hospital (SG)
  • Max Planck Institute of Biochemistry (DE)
Corresponding author
Chua, Boon Tin
Venue
Molecular Cancer
Published
2014-01-24
Volume
13
Issue
1
Pages
13-13
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2149055519
Cited by
59
References
32
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 3 · 2021: 9 · 2020: 9 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 4
FWCI
4.81
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion, cc-by)
  • Max Planck Digital Library (submittedVersion, other-oa)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
Funders
  • National Cancer Centre of Singapore
  • Medical Research Council
  • National Medical Research Council
  • Biomedical Research Council
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
bosutinib, ACK1, KRAS mutation, non-small cell lung cancer, lung adenocarcinoma, cell migration, cell invasion, non-receptor tyrosine kinase, prognostic factors, survival, combination therapy
MeSH terms
Aniline Compounds, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cell Movement, Humans, Lung Neoplasms, Mutation, Neoplasm Invasiveness, Nitriles, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Quinolines, Zebrafish, Blotting, Western, Proto-Oncogene Proteins p21(ras), ras Proteins, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tissue Array Analysis, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. https://app.cochat.ai/papers/10.1186/1476-4598-13-13
The paper
Tan, D. S., Haaland, B., Gan, J. M., Tham, S. C., Sinha, I., Tan, E. H., Lim, K. H., Takano, A., Krisna, S. S., Thu, M. M. M., Liew, H. P., Ullrich, A., Lim, W.-T., & Chua, B. T. (2014). Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Molecular Cancer. https://doi.org/10.1186/1476-4598-13-13

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.